Latest headlines
GSK plc News
The latest GSK plc (GSK) news, aggregated as it breaks. News moves sentiment and sentiment moves price, so read these GSK headlines next to the live GSK plc Fear and Greed Index.
Latest GSK plc Headlines60
GSK's targeted cancer therapy shows positive results in late-stage study
reuters.com · Jul 10, 2026
Alector and GSK partnership to end after dementia, Alzheimer's drug failures
reuters.com · Jul 8, 2026
Sino Biopharmaceutical, GSK expand alliance with China rights to respiratory drugs
reuters.com · Jul 8, 2026
Is GSK Quietly Becoming An Oncology Powerhouse
seekingalpha.com · Jun 25, 2026
Spero Therapeutics: Yesterday's Selloff On Utebzi Approval Seems Bewildering
seekingalpha.com · Jun 18, 2026
Biogen to Strengthen Immunology Pipeline With $1B RayThera Buyout
zacks.com · Jun 18, 2026
GSK's Utebzi Wins FDA Nod for Complicated Urinary Tract Infections
zacks.com · Jun 18, 2026
Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)
businesswire.com · Jun 17, 2026
Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)
globenewswire.com · Jun 17, 2026
US FDA approves GSK's oral antibiotic for drug-resistant UTIs
reuters.com · Jun 17, 2026
FDA Accepts Gilead's Filing for Weekly Oral Yeztugo for HIV Prevention
zacks.com · Jun 16, 2026
GSK's Momelotinib Gets Orphan Tag for Rare Hemato-Inflammatory Disorder
zacks.com · Jun 12, 2026
Is GSK PLC (GSK) Overvalued After 3.3% Rally? GF Value Says Overvalued
gurufocus.com · Jun 11, 2026
Pharma and Biotech M&A Boom Accelerates as Companies Expand Pipelines
zacks.com · Jun 11, 2026
Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion
marketbeat.com · Jun 11, 2026
Project Nashville: GSK boosts oncology rebuild with $11 billion Nuvalent deal
reuters.com · Jun 11, 2026
GSK plc (GSK) M&A Call Transcript
seekingalpha.com · Jun 10, 2026
Nuvalent Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nuvalent, Inc. - NUVL
businesswire.com · Jun 10, 2026
GSK's Nuvalent deal tackles HIV cliff to win cautious backing from analysts
proactiveinvestors.co.uk · Jun 10, 2026
Thistle Resources intersects broad gold mineralization at Middle River
proactiveinvestors.com · Jun 10, 2026
Snail Games brings Bellwright to PlayStation and Xbox as console push advances
proactiveinvestors.com · Jun 10, 2026
Lisata Therapeutics agrees to Kuva Labs buyout at $4 per share
proactiveinvestors.com · Jun 10, 2026
Abacus Global Management launches AI lifespan modeling platform
proactiveinvestors.com · Jun 10, 2026
After shedding its cancer business just over a decade ago, GSK's new CEO is building back with a $10.6 billion deal
wsj.com · Jun 9, 2026
Gilead, Merck Report Positive Phase III HIV Study Data, End NSCLC Study
zacks.com · Jun 9, 2026
GSK to Strengthen Oncology Pipeline With $10.6B Nuvalent Buyout
zacks.com · Jun 9, 2026
GSK Acquires Nuvalent for $10.6 Billion to Enhance Cancer Pipeline
gurufocus.com · Jun 9, 2026
Tuesday's Morning Movers: MU Rebounds, ON PT Increases & GSK Buys NUVL
youtube.com · Jun 9, 2026
5 Things to Know Before the Stock Market Opens
investopedia.com · Jun 9, 2026
Nuvalent Catapults To Record High On GSK's $10.6 Billion All-Cash Bid
investors.com · Jun 9, 2026
Nuvalent Stock Soars on $10.6 Billion GSK Buyout
schaeffersresearch.com · Jun 9, 2026
GSK Agrees $10.6 Billion Nuvalent Deal at 40% Premium
gurufocus.com · Jun 9, 2026
Breakfast News: CRM & ACN Lead Wave Of M&A Action
fool.com · Jun 9, 2026
GSK's $10.6B Nuvalent takeover fails to impress investors as shares fall: here's why
invezz.com · Jun 9, 2026
Cancer-Drug Stock Jumps 39% on $10.6 Billion GSK Deal. Why It's a Surprise Move.
barrons.com · Jun 9, 2026
GSK falls as £8bn takeover of Nuvalent is largest deal in a decade
proactiveinvestors.com · Jun 9, 2026
London's FTSE 100 falls as GSK slides after Nuvalent deal
invezz.com · Jun 9, 2026
GSK just announced its biggest purchase in eight years to rev up cancer portfolio it had previously wound down
marketwatch.com · Jun 9, 2026
GSK agrees $10.6bn Nuvalent takeover to bolster oncology pipeline
proactiveinvestors.co.uk · Jun 9, 2026
GSK to Buy Nuvalent for $10.6 Billion in Oncology Push
wsj.com · Jun 9, 2026
UK's GSK to buy US-based cancer drugmaker Nuvalent for $10.6 billion
reuters.com · Jun 9, 2026
GSK in talks to acquire Nuvalent for more than $9 billion in biggest deal in over a decade: FT
cnbc.com · Jun 9, 2026
GSK in talks to buy cancer biotech Nuvalent for more than $9 billion, FT reports
reuters.com · Jun 8, 2026
Engitix Announces Strategic Collaboration with GSK to Advance First-in-Class Targets for Liver Fibrosis Regression
globenewswire.com · Jun 8, 2026
Longspur initiates on Gelion with 153p target, saying its battery tech can undercut China
proactiveinvestors.com · Jun 4, 2026
FTSE 100 drops amid China banking concerns and falling oil prices
invezz.com · Jun 4, 2026
US bank sees GSK oncology pipeline as major value driver after New York conference
proactiveinvestors.com · Jun 4, 2026
US bank sees GSK oncology pipeline as major value driver after New York conference
proactiveinvestors.co.uk · Jun 4, 2026
Gunnison Copper targets resource expansion with new district-wide drill program at flagship Arizona project
proactiveinvestors.com · Jun 4, 2026
GSK plc (GSK) Presents at Jefferies Global Healthcare Conference 2026 Transcript
seekingalpha.com · Jun 3, 2026
GSK Bets on Specialty Medicines to Drive Long-Term Revenue Growth
zacks.com · Jun 3, 2026
UBS says UK stocks are better supported but not broadly so, as earnings lead while sentiment drags
proactiveinvestors.co.uk · Jun 3, 2026
Why Is Glaxo (GSK) Down 2.1% Since Last Earnings Report?
zacks.com · May 29, 2026
GSK hepatitis B drug a long-term opportunity but US bank holds back from upgrading
proactiveinvestors.com · May 29, 2026
GSK hepatitis B drug a long-term opportunity but US bank holds back from upgrading
proactiveinvestors.co.uk · May 29, 2026
Sonoro Gold upsizes private placement to C$15M amid investor demand
proactiveinvestors.com · May 29, 2026
GSK Drug Shows 19%-20% Hepatitis B Cure Rate In Late-Stage Trials
gurufocus.com · May 28, 2026
GSK plc (GSK) Discusses Bepirovirsen Phase III Data and Advances in Hepatitis B Treatment Transcript
seekingalpha.com · May 28, 2026
GSK Says Hepatitis B Drug Candidate Cured Some Patients in Late-Stage Trials
wsj.com · May 28, 2026
Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B
businesswire.com · May 28, 2026
Why Is GSK plc Up or Down Today?
When GSK plc (GSK) moves sharply, the reason is almost always in the headlines above. Earnings, guidance, analyst upgrades and downgrades, product news and macro data are the usual drivers of a GSK move on the day. The feed shows what broke and when, and the sentiment tag on each story shows whether the coverage skews positive or negative, so you can see at a glance why GSK plc is up or down today.
How GSK plc News Affects the Price
News does not move the GSK plc (GSK) price directly, it moves sentiment, and sentiment moves price. A run of negative headlines pulls the GSK plc Fear and Greed Index toward fear, while positive coverage pushes it toward greed, often before the price has fully reacted. A surprise story usually shows up first as a spike in GSK plc trading volume. That is the chain to watch: headline, sentiment, volume, then the GSK price.
Trade the GSK plc News With Sentiment
Headlines tell you what happened; the Fear and Greed Index tells you how the crowd is reacting. Watch GSK plc trading volume spike on a big story, check the GSK plc price history for context, follow the live GSK price, see the GSK plc price prediction, and read the GSK plc Fear and Greed Index for mood.
How do you feel about GSK plc?
1DFrequently asked questions
Why is GSK plc up or down today?
What is the latest GSK plc news?
Where does GSK plc news come from?
How often is GSK plc news updated?
How does GSK plc news relate to its Fear and Greed Index?
Headlines are aggregated from third-party sources and link to the original publishers. CFGI does not author or endorse them.
About CFGI
The per-asset sentiment record.
CFGI is a market sentiment data company that scores crowd emotion from 0 to 100 across crypto and stock markets. Crypto readings cover the whole market and hundreds of individual assets across 15-minute, 1-hour, 4-hour and daily views. The stock index gives a live daily reading for wider stock market sentiment.
Every CFGI score is built from 10 indicators: price, volatility, volume, impulse, technical analysis, social media, dominance, search interest, whale movements and order book pressure. The same data powers our API, alerts and embeddable widgets.